(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)
`
`ANY UA AAATTA AETI
`
`(10) International Publication Number
`WO 2021/048402 Al
`
`= a
`
`WIPOIPCT
`
`(19) World Intellectual Property
`Organization
`International Bureau
`
`(43) International Publication Date
`18 March 2021 (18.03.2021)
`
`SD)
`
`International Patent Classification:
`AGIK 39/12 (2006.01)
`AGIP 31/14 (2006.01)
`
`(21)
`
`International Application Number:
`
`PCT/EP2020/075541
`
`(22)
`
`International Filing Date:
`11 September 2020 (11.09.2020)
`
`(84)
`
`(25)
`
`Filing Language:
`
`(26)
`
`Publication Language:
`
`English
`
`English
`
`(30) Priority Data:
`19197202.5
`.
`(71) Applicant: KATHOLIEKE UNIVERSITEIT LEUVEN
`[BE/BE]; KU Leuven R&D Waaistraat 6 - box 5105, 3000
`Leuven Vlaams-Brabant(BE).
`
`13 September 2019 (13.09.2019) EP
`
`(72)
`
`(81)
`
`Inventors: DALLMEIER,Kai; Lovensveldstraat 5, 3010
`Kesscl-Lo (BE). LEMMENS, Viktor; Gcldcnaakscvest 78,
`3000 Leuven (BE). NEYTS, Johan; Heidebergstraat 278,
`3010 Kessel-Lo (BE). SANCHEZ FELIPE, Lorena; Wi-
`jveld 15, 3018 Wijgmaal (BE).
`
`Designated States (unless otherwise indicated, for every
`kind of national protection available): AE, AG, AL, AM,
`AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
`CA,CII, CL, CN, CO, CR, CU, CZ, DE, DJ, DK, DM, DO,
`DZ, EC, EE, EG, ES, FL, GB, GD, GE, GH, GM, GT, HN,
`
`(54) Title: LASSAVIRUS VACCINES
`
`HR, HU,ID, IL, IN,IR, IS, IT, JO, JP, KE, KG, KH, KN,
`KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY, MA, MD,
`ME, MG, MK, MN, MW, MX, MY, MZ, NA, NG, NI, NO,
`NZ, OM,PA, PE, PG, PH, PL, PT, QA, RO, RS, RU, RW,
`SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH, TJ, TM, TN,
`TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS, ZA, ZM, ZW.
`
`Designated States (unless otherwise indicated, for every
`kind of regional protection available); ARIPO (BW, GH,
`GM,KE, LR, LS, MW, MZ, NA, RW,SD, SL, ST, SZ, TZ,
`UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ, RU, TJ,
`TM), European (AL, AT, BE, BG, CH, CY, CZ, DE, DK,
`EE, ES, FI, FR, GB, GR, HR, HU,IE, IS, IT, LT, LU, LV,
`MC, MK,MT, NL, NO,PL, PT, RO, RS, SE, SI, SK, SM,
`TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW,
`KM,ML, MR, NE, SN, TD, TG).
`
`Declarations under Rule 4.17:
`
`ofinventorship (Rule 4.17(iv))
`Published:
`
`with international search report (Art. 21(3))
`before the expiration of the time limit for amending the
`claims and to be republished in the event ofreceipt of
`amendments (Rule 48.2(h))
`with sequence listing part ofdescription (Rule 5.2(a))
`
`~~
`
`2 1000
`gs
`
`e 2o
`
`a?
`a™
`
`* r3o
`
`O
`
`“
`
`BM euiav-tasv
`© YEV17D/LASV
`
`
`
`YEV NS3
`
`LASV GPC
`
`OVA
`
`Figure 4B
`
`500
`
`0
`
`wo2021/048402A.lIITNIMINIIIUIURITATYAAAIATAA
`
`
`
`
`
`(57) Abstract: The present invention relates to polynucleotides comprising a sequence ofalive, infectious, attenuated Flavivirus
`wherein a nucleotide sequence encoding at least a part of a arenavirus glycoprotein protein is located at the intergenic region between
`the E and NS1 gene of said Flavivirus, such that a chimeric virus is expressed, characterised in that the encoded sequence C terminally
`of the E protein of said Flavivirus and N terminally of the signal peptide of the NS1 protein of said Flavivirus comprises in the following
`order: - a further signal peptide of a Flavivirus NS1 protein, -an arenavirus Glycoprotein protein lacking the N terminal signal sequence
`and the GP2 transmembrane domain, - a TM1 and TM2 domain ofa flaviviral E protein.
`
`
